Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy. Also, the Company Announced That It Accepted an Unsolicited Offer From an Institutional Investor to Purchase 22,222,222 Shares of Stock at $9.00 per Share and Will Use the Net Proceeds to Advance Clinical Development of Ivonescimab.
Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.